Dc-Cik
Multiple Drug Use
Tianjin Medical University Cancer Institute and HospitalCell therapyPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Multiple Drug Use cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Licartin Tianjin Medical University Cancer Institute and Hospital | Phase 4 | BB |
Same molecule, other indications
Dc-Cik is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →